Channel Therapeutics CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Ezra Friedberg of Pelthos Therapeutics Inc. reported the sale of 534 shares of common stock on July 2, 2026, for an aggregate price of $26.0303 per share, as part of a pre-arranged 10b5-1 plan.
Pelthos Therapeutics Director Matthew Pauls reported the sale of company common stock valued at over $1.8 million, executed under a pre-arranged trading plan.
Pelthos Therapeutics Director Peter Greenleaf reported a sale of common stock valued at approximately $18,500, executed under a Rule 10b5-1 trading plan.
Director Ezra M. Friedberg sold 283 shares of Pelthos Therapeutics Inc. to satisfy tax obligations related to RSU vesting.
Director Todd Davis purchased 35,948 shares of Pelthos Therapeutics common stock in open market transactions.
Pelthos Therapeutics Inc. reports changes in beneficial ownership for CFO Francis Knuettel II, including stock option acceleration and share sales upon his departure.
Director Ezra Friedberg sold 144 shares of Pelthos Therapeutics Inc. to satisfy tax obligations related to RSU vesting.
Richard Malamut, a Director at Pelthos Therapeutics Inc., reported the sale of company stock totaling 1,320 shares on April 2, 2026, executed under a pre-arranged 10b5-1 trading plan.
Director Ezra Friedberg of Pelthos Therapeutics Inc. reported the sale of company stock under a pre-arranged trading plan to cover tax obligations.
Pelthos Therapeutics Director Matthew Pauls reported the sale of company stock totaling 786 shares, executed under a pre-arranged Rule 10b5-1 trading plan.
Pelthos Therapeutics Director Peter Greenleaf sold shares valued at over $8.6 million through a pre-arranged plan to cover tax obligations.
Ezra M. Friedberg, a director at Pelthos Therapeutics Inc., filed an amended Form 4 to correctly report previously granted restricted stock units as direct beneficial ownership.
Pelthos Therapeutics Inc. Director Todd C. Davis filed an amended Form 4 to correctly report restricted stock unit grants as direct beneficial ownership.
Pelthos Therapeutics Inc. Director Richard Malamut filed an amended Form 4 to correctly report restricted stock unit grants in Table I, reflecting recent acquisitions and a 1-for-10 reverse stock split.
Pelthos Therapeutics Inc. CEO Scott M. Plesha filed an amended Form 4 to correctly report the grant of 83,678 restricted stock units as direct common stock ownership.
Pelthos Therapeutics Inc. Director Peter Greenleaf filed an amended Form 4 to correctly report 25,478 restricted stock units as common stock in Table I.
Pelthos Therapeutics Director Matthew Pauls amended a Form 4 to correctly report the grant of 25,478 restricted stock units as common stock.
Pelthos Therapeutics' Chief Commercial Officer, Sai Rangarao, filed an amended Form 4 to correctly report the grant of 30,518 restricted stock units as common stock.
Pelthos Therapeutics Inc. Director Richard B. Baxter amended a Form 4 to correctly report the acquisition of 19,108 common stock shares from restricted stock units.
Pelthos Therapeutics CFO Francis Knuettel II filed an amendment to correctly report the grant of 33,472 restricted stock units as direct beneficial ownership.
Pelthos Therapeutics director Andrew J. Einhorn received a grant of 12,000 Restricted Stock Units as compensation for his board service.
Pelthos Therapeutics shareholders approved a waiver, leading to a reduced conversion price for Ligand Pharmaceuticals' senior secured convertible note.
Pelthos Therapeutics Inc. Director Matthew Pauls reported the vesting of restricted stock units and a gift of 9,542 common shares to a trust.
Pelthos Therapeutics director Ezra M. Friedberg sold 10,000 shares of common stock for approximately $280,000 through pre-arranged plans.
Ligand Pharmaceuticals Inc. acquired a $9 million senior secured convertible note in Pelthos Therapeutics Inc., convertible into common stock at $34.442 per share.
Pelthos Therapeutics Inc. CEO and President Scott M. Plesha received grants of 83,678 restricted stock units and 255,000 stock options, aligning executive incentives with shareholder value.
Pelthos Therapeutics Inc.'s Chief Commercial Officer, Sai Rangarao, was granted 30,518 restricted stock units and 93,000 stock options, both with an exercise price of $13.50 per share.
Richard B. Baxter, a Director at Pelthos Therapeutics Inc., was granted 19,108 restricted stock units and 58,230 stock options, aligning his interests with long-term shareholder value.
Pelthos Therapeutics Inc. Director Peter Greenleaf was granted 25,478 restricted stock units and 77,640 stock options, both with an exercise price of $13.50 per share, as part of his compensation.
Pelthos Therapeutics Inc. Director Matthew Pauls was granted 25,478 restricted stock units and 77,640 stock options, both with an exercise price of $13.50 per share, aligning his interests with shareholders.